Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?"

J Hepatol. 2022 Jul;77(1):258-259. doi: 10.1016/j.jhep.2022.02.025. Epub 2022 Mar 10.
No abstract available

Publication types

  • Letter
  • Kommentar

MeSH terms

  • Antiviral Agents / adverse effects
  • Hepacivirus
  • Hepatitis C, Chronic* / complications
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / drug therapy
  • Sustained Virologic Response

Substances

  • Antiviral Agents